What's Happening?
A recent study published in JAMA Psychiatry, led by Beth Han and Dr. Nora Volkow, director of the National Institute on Drug Abuse, analyzed data from over 186,000 U.S. adults between 2021 and 2024, revealing a significant shift in substance use disorders.
While alcohol use disorder saw a modest decline from 28.8 million to 27.1 million adults, cannabis use disorder sharply increased from 15.3 million to 19.4 million adults, a rise of over 25%. The increase was particularly pronounced among certain demographics: moderate-to-severe cannabis use disorder rose by approximately 32% among men and 47% among women. Notably, among women aged 50 and older, this disorder increased sevenfold, from 0.1% to 0.7% of that population, in just three years. Dr. Volkow emphasized that the perception of cannabis as non-addictive may be incorrect, highlighting a growing public health concern that often goes unaddressed in workplaces and treatment settings.
Why It's Important?
This shift has significant implications for public health, workplace policies, and the healthcare system in the U.S. The rise in cannabis use disorder, particularly among older women, indicates a demographic expansion of the problem that challenges existing assumptions about substance abuse. For employers, the data suggests a blind spot, as many companies do not systematically track substance use risk and may be operating under the false premise that declining alcohol consumption equates to reduced overall risk. The absence of FDA-approved Medication Assisted Treatment (MAT) for cannabis use disorder further complicates the issue, placing greater reliance on early intervention, screening, and non-pharmacological support like peer programs. The societal destigmatization and increasing legality of cannabis may also contribute to a perception that it is less harmful, potentially delaying individuals from seeking help and exacerbating the problem.
What's Next?
The findings call for a re-evaluation of public health strategies and workplace wellness programs. Increased awareness campaigns are likely needed to educate the public, including employers and healthcare providers, about the addictive potential of cannabis. Research into effective treatments for cannabis use disorder, including pharmacological interventions, will become more critical. Workplaces may need to update their substance use policies to include cannabis, offering confidential support and resources for employees struggling with addiction. The healthcare system will also need to adapt, providing more comprehensive screening and treatment options for cannabis use disorder, moving beyond the traditional focus on alcohol and opioids. Furthermore, the legal and cultural landscape surrounding cannabis may face renewed scrutiny as the public health implications become more apparent.
Beyond the Headlines
The surge in cannabis use disorder highlights a broader societal challenge in how substances are perceived and regulated. The ease of obtaining medical cannabis cards in many areas, coupled with its growing cultural acceptance, may inadvertently contribute to a downplaying of its addictive potential. This creates a paradox where a substance is simultaneously viewed as a therapeutic agent and a potential source of addiction. The stigma associated with cannabis use disorder, even within recovery communities, further complicates treatment efforts, as it may not be seen as a 'real' drug problem compared to opioid or stimulant addictions. This underscores the need for a more nuanced understanding of addiction, recognizing that the substance itself does not define the severity of the disorder. The data also prompts a re-examination of harm reduction strategies, acknowledging that while cannabis may be a lower-risk alternative to other substances for some, it can still lead to significant problems on its own.
